Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Night Writer who wrote (8051)	7/12/1999 6:20:00 PM
From: SJS	Read Replies (1) \| Respond to of 9523

I heard on another board it's now Friday. Can you confirm?

To: Night Writer who wrote (8051)	7/12/1999 6:22:00 PM
From: Bretsky	Read Replies (1) \| Respond to of 9523

I CAN"T FIND ANYTHING EITHER...SOMEONE HELP, WHEN IS PFE REPORTING ?

To: Night Writer who wrote (8051)	7/12/1999 6:29:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

The only date we can be sure of is sometime this week (or even next week). The dates provided by various financial sites are guesses only. PFE normally doesn't pre-announce the date.

To: Night Writer who wrote (8051)	7/12/1999 6:31:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 9523

Pfizer 2nd-Qtr Net Seen at 17 Cents a Share: Earnings Outlook Bloomberg News July 12, 1999, 4:38 p.m. ET New York, July 12 (Bloomberg) -- The following is a preview of earnings expectations for Pfizer Inc. Expected Earnings Pfizer Inc.'s second-quarter earnings are expected to rise to 17 cents a share, the average estimate of analysts polled by First Call Corp. The No. 2 U.S. drugmaker after Merck & Co. earned 16 cents, adjusted for a three-for-one stock split, according to First Call. Time Pfizer, maker of the impotence pill Viagra and the antidepressant Zoloft, is expected to release earnings this week or early next week. Behind the Numbers Pfizer warned in April that its second-quarter profit would rise 9 percent or less, surprising analysts who had expected a 20 percent increase, as the company faced the comparison with the record-setting introduction of Viagra in the second quarter of 1998. Introduced in April 1998, the drug had second-quarter sales of $411 million as news stories spurred demand. In the second quarter of 1999, Viagra sales could be about $250 million, said Neil Sweig, an analyst with Southeast Research Partners. In the quarter, Pfizer had a setback with its new antibiotic, Trovan. The U.S. Food and Drug Administration last month said Trovan should only be used to treat patients with serious or life-threatening illnesses because of concerns about liver damage. The sales of some of its biggest products, such as the high- blood-pressure medicine Norvasc, have been rising. Under Chief Executive William Steere, Pfizer has been channeling its profits from Norvasc and other blockbusters such as the antidepressant Zoloft back into building its drug research. It will spend $2.8 billion in 1999 on the hunt for new medicines. What the Experts Say ''The company is doing very well, but it's not going to be a great quarter because of the Viagra comparisons,'' said Hemant Shah, an independent analyst with a ''neutral'' rating on the stock. Previous Market Reaction Pfizer fell 4 7/8 to 43 21/64, adjusted for its three-for- one stock split, on April 15 after reporting that first-quarter profit rose 18 percent to $815 million, or 62 cents a share. Market Trend Pfizer shares have declined 10 percent this year to 37 3/8 amid concerns that proposed reforms of Medicare, a U.S. government health-benefit for the elderly, will cut drugmakers' profits. The stock also has fallen on concerns about Trovan, which some analysts once saw as a potential blockbuster.